GIST

Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.

An Orphan Drug Designation was granted by the FDA to ilixadencel as use for the treatment of patients with soft tissue sarcoma.

For patients with advanced gastrointestinal stromal tumors, there was continued clinically meaningful benefit with the novel broad-spectrum KIT and PDGFRα inhibitor ripretinib in the fourth line or later, according to updated data from the randomized phase 3 INVICTUS trial presented at the 2020 ESMO Virtual Congress.

In an interview with Targeted Oncology, Ping Chi, MD medical oncologist, Geoffrey Beene Junior Faculty chair, Memorial Sloan Kettering Cancer Center, discussed the phase 2 study of binimetinib in combination with imatinib in patients with untreated advanced GIST.

Neeta Somaiah, MD, reviews the case of a 68-year-old man with gastrointestinal stromal tumor.

“The data presented today further reinforce the potential of ripretinib to provide meaningful clinical benefit to patients with advanced gastrointestinal stromal tumor."

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.

"Today’s approval of Qinlock establishes a new standard of care for patients who have received three prior therapies."